AXIM® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
09 mai 2019 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today announced...
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
06 mai 2019 07h00 HE
|
Axsome Therapeutics, Inc.
Topline results now anticipated in 2H 2019 Trial enriched with only patients with history of inadequate response to prior migraine treatments Trial compares AXS-07 to placebo and active comparator ...
Trevena Reports Fourth Quarter and Full Year 2018 Results
13 mars 2019 07h00 HE
|
Trevena Inc.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...
Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine
04 mars 2019 07h00 HE
|
Axsome Therapeutics, Inc.
First patient enrolled in the MOMENTUM study Trial being conducted under FDA Special Protocol Assessment (SPA) Topline results anticipated in 1Q 2020 NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) --...
Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
06 févr. 2019 07h00 HE
|
Axsome Therapeutics, Inc.
FDA agreement achieved on Phase 3 trial design, endpoints, and statistical approach Trial to enroll patients with a history of inadequate response to prior migraine treatments Trial initiation...
New Online Resource Tool Available for Persons with Migraine Disease to Help Address Healthcare Challenges
07 janv. 2019 05h00 HE
|
Patient Advocate Foundation
Hampton, VA, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Patient Advocate Foundation (PAF) is excited to announce the launch of its new interactive educational widget, Migraine Matters, that empowers those...
IntelGenx Partners with Gensco® Pharma to Market RIZAPORT® in the United States
12 déc. 2018 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Dec. 12, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced the execution of a definitive...
IntelGenx Announces FDA’s Acceptance of Resubmission of New Drug Application for RIZAPORT®
20 nov. 2018 08h00 HE
|
IntelGenx Technologies Corp.
- PDUFA Goal Date of April 1, 2019 - SAINT LAURENT, Quebec, Nov. 20, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced that its...
The Spanish Agency of Medicines and Medical Devices Grants Marketing Authorization of RIZAPORT®
31 oct. 2018 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Oct. 31, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) is pleased to announced that its commercialization partner for...
IntelGenx Announces Successful Results from RIZAPORT® Bioequivalence Study
24 sept. 2018 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Sept. 24, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced successful results from a bioequivalence study for...